GSK Unveils Final Results From Four-year CombAT Study For BPH

GlaxoSmithKline (GSK) has reported the final results from its four-year CombAT (Combination therapy with Avodart and Tamsulosin) study.

The results show that combined treatment with Avodart and tamsulosin significantly reduces the risk of acute urinary retention (AUR) or Benign Prostatic Hyperplasia (BPH) related surgery by 66%, compared to tamsulosin alone. It also indicated that combination therapy significantly reduces the risk of BPH disease progression by 44%, compared to tamsulosin, and 31% compared to dutasteride alone.

Reportedly, all men in this study had moderate-to-severe symptoms of BPH at enrollment. Those treated with combination therapy reported a significant improvement in BPH symptoms at four years, as measured by the International Prostate Symptom Score (IPSS), with a mean change from baseline of -6.3 points, compared to -3.8 for tamsulosin and -5.3 for dutasteride alone.

The study results suggested that the combination therapy was generally well-tolerated and most reported drug-related adverse events were as anticipated from the known safety profiles of the two drugs.

Claus Roehrborn, principle investigator and lead author of the CombAT study publication, said: “BPH is a progressive disease causing discomfort, inconvenience and embarrassment for many men. CombAT provides evidence that combination therapy may benefit these men, potentially reducing the long-term risk of disease progression and improving their symptoms.”